WOCKPHARMA has completed a long term correction cycle and now could be a good buy with targets above 2,000 in the long term. The invalidation for this analysis remains at 135.20 (marked level).
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。